Vincent Pillonel

Vincent Pillonel

Auto-generated profile, based on publicly available information

Vincent Pillonel

Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
VPV. Pillonel
V. Pillonel
DJDarius Juskevicius
Darius Juskevicius
CNC. K. Y. Ng
C. K. Y. Ng
ABA. Bodmer
A. Bodmer
AZA. Zettl
A. Zettl
Alexandar TzankovAlexandar Tzankov
Alexandar Tzankov
Nodal marginal zone lymphoma (NMZL) is a rare small B-cell lymphoma lacking disease-defining phenotype and precise diagnostic markers. To better understand the mutational landscape of NMZL, particularly in comparison to other nodal small B-cell lymphomas, we performed whole-exome sequencing, targeted high-throughput sequencing, and array-comparative genomic hybridization on a retrospective series. Our study identified for the first time recurrent, diagnostically useful, and potentially therapeutically relevant BRAF mutations in NMZL. Sets of somatic mutations that could help to discriminate NMZL from other closely related small B-cell lymphomas were uncovered and tested on unclassifiable small B-cell lymphoma cases, in which clinical, morphological, and phenotypical features were equivocal. Application of targeted gene panel sequencing gave at many occasions valuable clues for more specific classification.

2 December 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
VPVincent Pillonel
Vincent Pillonel
VDVincent Dunet
Vincent Dunet
AHAndreas F. Hottinger
Andreas F. Hottinger
GBGregoire Berthod
Gregoire Berthod
LSLuis Schiappacasse
Luis Schiappacasse
VAVeronica Aedo-Lopez
Veronica Aedo-Lopez
Background Immune checkpoint inhibitors (ICPis) have revolutionised the treatment of melanoma by significantly increasing survival rates and disease control. However, ICPis can have specific immune-related adverse events, including rare but severe neurological toxicity. Case presentation We report a 44-year-old man diagnosed with stage IIIB melanoma who developed metastatic disease (pulmonary and brain metastases) and was treated with stereotactic radiosurgery and nivolumab immunotherapy. He developed asymptomatic multifocal diffuse white matter lesions consistent with active central nervous system demyelination seen on brain MRI. One month after cessation of the immunotherapy, spontaneous regression of the demyelinating lesions was observed, suggesting a nivolumab-related toxicity. Conclusion We report the first case of a melanoma patient with an asymptomatic and spontaneously reversible central nervous system demyelination following nivolumab immunotherapy. This case highlights the need for better recognition of such atypical and rare neurological toxicities which could be mistaken for progressive brain metastases. Early recognition and appropriate management are crucial to reduce severity and duration of these toxicities, especially for patients with less favourable evolution.

4 July 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
VPVincent Pillonel
Vincent Pillonel
DJDarius Juskevicius
Darius Juskevicius
MBMichel Bihl
Michel Bihl
FSFrank Stenner
Frank Stenner
JHJörg P. Halter
Jörg P. Halter
Alexandar TzankovAlexandar Tzankov
Alexandar Tzankov
Since 2016, a next-generation sequencing (NGS) panel targeting 68 genes frequently mutated in lymphoid malignancies is an accredited part of routine diagnostics at the Institute of Pathology in Basel, Switzerland. Here, we retrospectively evaluate the feasibility and utility of integrating this NGS platform into routine practice on 80 diagnostic cases of lymphoid proliferations. NGS analysis was useful in most instances, yielding a diagnostically, predictively and/or prognostically meaningful result. In 35 out of the 50 cases, in which conventional histopathological evaluation remained indecisive, molecular subtyping with the NGS panel was helpful to either confirm or support the favored diagnosis, enable a differential diagnosis, or seriously question a suspected diagnosis. A total of 61 actionable or potentially actionable mutations in 34 out of 80 cases that might have enabled patient selection for targeted therapies was detected. NGS panel analysis had implications for prognosis in all 15 cases interrogated for risk assessment.

25 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VPVincent Pillonel
Vincent Pillonel
NRNina Reichert
Nina Reichert
CCChun Cao
Chun Cao
MHMarinus R. Heideman
Marinus R. Heideman
TYTeppei Yamaguchi
Teppei Yamaguchi
PMPatrick Matthias
Patrick Matthias
The two histone deacetylases (Hdacs), Hdac1 and Hdac2, are erasers of acetylation marks on histone tails, and are important regulators of gene expression that were shown to play important roles in hematological malignancies. However, several recent studies reported opposing tumor-suppressive or tumor-promoting roles for Hdac1 and Hdac2. Here, we investigated the functional role of Hdac1 and Hdac2 using the Eμ-myc mouse model of B cell lymphoma. We demonstrate that Hdac1 and Hdac2 have a pro-oncogenic role in both Eμ-myc tumorigenesis and tumor maintenance. Hdac1 and Hdac2 promote tumorigenesis in a gene dose-dependent manner, with a predominant function of Hdac1. Our data show that Hdac1 and Hdac2 impact on Eμ-myc B cell proliferation and apoptosis and suggest that a critical level of Hdac activity may be required for Eμ-myc tumorigenesis and proper B cell development. This provides the rationale for utilization of selective Hdac1 and Hdac2 inhibitors in the treatment of hematological malignancies.

18 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CRCamille Du Roure
Camille Du Roure
AVAude Versavel
Aude Versavel
TDThierry Doll
Thierry Doll
CCChun Cao
Chun Cao
VPVincent Pillonel
Vincent Pillonel
PMPatrick Matthias
Patrick Matthias
We have identified expression of the gene encoding the transcriptional coactivator FOG-1 (Friend of GATA-1; Zfpm1, Zinc finger protein multitype 1) in B lymphocytes. We found that FOG-1 expression is directly or indirectly dependent on the B cell-specific coactivator OBF-1 and that it is modulated during B cell development: expression is observed in early but not in late stages of B cell development. To directly test in vivo the role of FOG-1 in B lymphocytes, we developed a novel embryonic stem cell recombination system. For this, we combined homologous recombination with the FLP recombinase activity to rapidly generate embryonic stem cell lines carrying a Cre-inducible transgene at the Rosa26 locus. Using this system, we successfully generated transgenic mice where FOG-1 is conditionally overexpressed in mature B-cells or in the entire hematopoietic system. While overexpression of FOG-1 in B cells did not significantly affect B cell development or function, we found that enforced expression of FOG-1 throughout all hematopoietic lineages led to a reduction in the number of circulating eosinophils, confirming and extending to mammals the known function of FOG-1 in this lineage.